Hallucinogens approved for treating psychiatric disorders: What does the science say?

Once sidelined in the 1970s, psychedelic substances—ranging from esketamine (a ketamine derivative) and psilocybin (the active ingredient in hallucinogenic mushrooms) to MDMA—are being reintroduced as potential therapies for severe psychiatric disorders…